Enzychem Lifesciences (CEO Ki-Young Son) announced on the 29th that it signed a memorandum of understanding (MOU) with the Daegu-Gyeongbuk Medical Industry Promotion Foundation New Drug Development Support Center (K-MEDI Hub) and Ajou University to establish a cooperative system for joint research and commercialization of new drug modalities based on Targeted Protein Degradation (TPD).
Through this agreement, the three organizations will pursue joint research on novel TPD-based drug modality technologies and engage in phased collaboration, including the discovery of new drug candidates and the examination of commercialization potential. Enzychem Lifesciences is strengthening its technology portfolio, focusing on next-generation innovative TPD-based drug modalities such as PROTAC (Proteolysis Targeting Chimera), and is securing global competitiveness through collaborations with specialized research institutes and universities.
TPD technology has the advantage of targeting targets difficult to access with existing therapies by selectively removing specific proteins through intracellular degradation systems. This technology is scalable to various new drug modalities, and its pipeline is highly likely to expand into various disease areas in the future.
An official from Enzychem Lifesciences said, “This agreement is an important first step toward securing innovative new drug modalities through industry-academia-research collaboration in the field of targeted protein degradation,” and added, “Based on the results of our joint research, we will build a competitive new drug pipeline in the global market.”
- See more related articles
You must be logged in to post a comment.